Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The primary objectives of this study are to evaluate the efficacy of filgotinib in the
induction and maintenance treatment of moderately to severely active ulcerative colitis (UC)
in participants who are biologic-naive and biologic-experienced.
Participants who complete the study, or met protocol specified efficacy discontinuation
criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead
Study GS-US-418-3899: NCT02914535).
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Gastrointestinal, Stomach, Esophageal
Enrollment Eligibility
Key Inclusion Criteria:
- Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on
the date of the screening visit
- Documented diagnosis of UC of at least 6 months AND with a minimum disease extent of
15 cm from the anal verge. Documentation should include endoscopic and histopathologic
evidence of UC.
- A surveillance colonoscopy is required at screening in individuals with a history of
UC for 8 or more years, if one was not performed in the prior 24 months
- Moderately to severely active UC
- Previously demonstrated an inadequate clinical response, loss of response to, or
intolerance to at least 1 of the following agents (depending on current country
treatment recommendations/guidelines): corticosteroids, immunomodulators, tumor
necrosis factor alpha (TNFa) antagonists, or vedolizumab
Key Exclusion Criteria:
- Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant
colitis, ulcerative proctitis, or toxic mega-colon
- Active tuberculosis (TB) or history of latent TB that has not been treated
- Use of any concomitant prohibited medications as described in the protocol
Note: Other protocol defined Inclusion/Exclusion criteria may apply.